Antibodies directed to B7-related polypeptide, BSL-2
The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
1. An isolated monoclonal antibody or fragment thereof that binds to the polypeptide set forth as SEQ ID NO:7, wherein said antibody is selected from the group consisting of:
a. an antibody produced by hybridoma cell line, 5D7E2, deposited under ATCC Deposit No. PTA-4057;
b. an antibody produced by hybridoma cell line, 1F7G2, deposited under ATCC Deposit No. PTA-4058;
c. an antibody produced by hybridoma cell line, 3E6D3, deposited under ATCC Deposit No. PTA-4059; and
d. an antibody produced by hybridoma cell line, 4C2C6, deposited under ATCC Deposit No. PTA-4060.
2. The isolated antibody or fragment thereof of claim 1 , wherein said antibody is set forth in claim 1 a.
3. The isolated antibody or fragment thereof of claim 1 , wherein said antibody is set forth in claim 1 b.
4. The isolated antibody or fragment thereof of claim 1 , wherein said antibody is set forth in claim 1 c.
5. The isolated antibody or fragment thereof of claim 1 , wherein said antibody is set forth in claim 1 d.
6. An isolated hybridoma cell line that produces a monoclonal antibody or fragment thereof that binds to the polypeptide provided as SEQ ID NO:7, wherein said hybridoma is selected from the group consisting of:
a. hybridoma cell line, 5D7E2, deposited under ATCC Deposit No. PTA-4057;
b. hybridoma cell line, 1F7G2, deposited under ATCC Deposit No. PTA-4058;
c. hybridoma cell line, 3E6D3, deposited under ATCC Deposit No. PTA-4059; and
d. hybridoma cell line, 4C2C6, deposited under ATCC Deposit No. PTA-4060.
7. The isolated hybridoma cell line of claim 6 , wherein said hybridoma cell line is set forth in claim 6 a.
8. The isolated hybridoma cell line of claim 6 , wherein said hybridoma cell line is set forth in claim 6 b.
9. The isolated hybridoma cell line of claim 6 , wherein said hybridoma cell line is set forth in claim 6 c.
10. The isolated hybridoma cell line of claim 6 , wherein said hybridoma cell line is set forth in claim 6 d.
11. A method of producing a monoclonal antibody capable of binding to the polypeptide set forth as SEQ ID NO:7 comprising the steps of:
a. incubating the hybridoma cell line of claim 7 under conditions in which an antibody will be expressed; and
b. recovering said antibody.
12. A method of producing a monoclonal capable of binding to the polypeptide set forth as SEQ ID NO:7 comprising the steps of:
a. incubating the hybridoma cell line of claim 8 under conditions in which an antibody will be expressed; and
b. recovering said antibody.
13. A method of producing a monoclonal capable of binding to the polypeptide set forth as SEQ ID NO:7 comprising the steps of:
a. incubating the hybridoma cell line of claim 9 under conditions in which an antibody will be expressed; and
b. recovering said antibody.
14. A method of producing a monoclonal capable of binding to the polypeptide set forth as SEQ ID NO:7 comprising the steps of:
a. incubating the hybridoma cell line of claim under conditions in which an antibody will be expressed; and
b. recovering said antibody.
15. A kit for detecting the polypeptide provided as SEQ ID NO:7 comprising:
a) the isolated antibody of claim 2 ; and
b) at least one component to detect binding of the isolated antibody to said polypeptide.
16. A kit for detecting the polypeptide provided as SEQ ID NO:7 comprising:
a.) the isolated antibody of claim 3 ; and
b.) at least one component to detect binding of the isolated antibody to said polypeptide.
17. A kit for detecting the polypeptide provided as SEQ ID NO:7 comprising:
a.) the isolated antibody of claim 4 ; and
b.) at least one component to detect binding of the isolated antibody to said polypeptide.
18. A kit for detecting the polypeptide provided as SEQ ID NO:7 comprising:
a.) the isolated antibody of claim 5 ; and
b.) at least one component to detect binding of the isolated antibody to said polypeptide.
19. A pharmaceutical composition comprising the antibody according to claim 2 , and a physiologically acceptable carrier, excipient, or diluent.
20. A pharmaceutical composition comprising the antibody according to claim 3 , and a physiologically acceptable carrier, excipient, or diluent.
21. A pharmaceutical composition comprising the antibody according to claim 4 , and a physiologically acceptable carrier, excipient, or diluent.
22. A pharmaceutical composition comprising the antibody according to claim 5 , and a physiologically acceptable carrier, excipient, or diluent.
23. A labeled antibody, comprising the antibody of claim 2 , 3 , 4 , or 5 , and comprising a label.
24. The labeled antibody of claim 23 , wherein said label is selected from the group consisting of: a) an enzyme; b) a fluorescent label; and c) a radioisotope.
25. The antibody or fragment thereof of claim 2 wherein the fragment is selected from the group consisting of group consisting of a Fab fragment, a F(ab′)2 fragment, and an Fv fragment.
26. The antibody or fragment thereof of claim 3 wherein the fragment is selected from the group consisting of group consisting of a Fab fragment, a F(ab′)2 fragment, and an Fv fragment.
27. The antibody or fragment thereof of claim 4 wherein the fragment is selected from the group consisting of a) a Fab fragment; b) a F(ab′) 2 fragment, and c) a Fv fragment.
28. The antibody or fragment thereof of claim 5 wherein the fragment is selected from the group consisting of a) a Fab fragment; b) a F(ab′)2 fragment, and c) a Fv fragment.